 Aethlon Medical, Inc. Nasdaq: AEMD, a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today released positive ex vivo data demonstrating the ability of a laboratory version of the Companys Hemopurifier to capture tumor-derived exosomes in several forms of cancer. The data were presented in e-poster format by Dr. Annette Marleau, the Companys Senior Director of Research, at the American Association for Cancer Research AACR Virtual Annual Meeting II, on June 22, 2020. 